Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kowa Co.,Ltd. (7807.T)
Osaka, JP
Kowa Co.,Ltd., together with its subsidiaries, manufactures and sells nursing care products and welfare equipment under the Tacaof, AURULA, and GENTIL MARRONE brands in Japan. It operates through Nursing Care and Equipment Manufacturing and Sales Business, Nursing Care Service Business, and E-Commerce EC segments. The company offers walking frames, walking aid and silver carts, and walking sticks. It also offers handle lifestyle support products, such as bathing, toileting, and medication support; bathing aids; excretion care; floor-related; and food and oral care products. In addition, the company provides walking vehicles, walking assistance carts, silver cars, handrails, walking sticks, bathing products, excretion products, and life support products. Kowa Co.,Ltd. was founded in 1965 and is headquartered in Osaka, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.71% | +0.48% | +2.94% | -1.87% | +3.45% | -1.53% | +7.98% | -4.66% | -5.20% | -72.79% | -72.79% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+0.4% Q1'26: -1.8% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-28.3% Q1'26: -11.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+11.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+11.7% Q1'26: +12.3% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+29.8% ★ Q1'26: +30.1% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%-3.3% ★ Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.21× ★ Q1'26: 0.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Feb 2018 actual |
Feb 2019 actual |
Feb 2020 actual |
Feb 2021 actual |
Feb 2022 actual |
|---|---|---|---|---|---|
| Revenue |
5.09B
est: 5.10B (-0.2%)
|
4.52B
est: 5.10B (-11.3%)
|
5.96B
est: 6.16B (-3.3%)
|
5.25B
est: 6.73B (-22.0%)
|
5.72B
est: 7.17B (-20.3%)
|
| EBITDA |
630.58M
est: 813.66M (-22.5%)
|
-185.89M
est: 813.66M (-122.8%)
|
115.89M
est: 983.42M (-88.2%)
|
579.57M
est: 1.07B (-46.0%)
|
838.64M
est: 1.14B (-26.7%)
|
| EBIT |
562.46M
est: 621.00M (-9.4%)
|
-272.88M
est: 621.00M (-143.9%)
|
-131.31M
est: 750.55M (-117.5%)
|
368.85M
est: 819.59M (-55.0%)
|
590.44M
est: 873.17M (-32.4%)
|
| Net Income |
356.40M
est: 356.91M (-0.1%)
|
-358.16M
est: 194.64M (-284.0%)
|
-367.33M
est: 232.45M (-258.0%)
|
389.40M
est: 229.44M (+69.7%)
|
400.96M
est: 377.68M (+6.2%)
|
| SGA |
2.08B
est: 1.59B (+31.1%)
|
2.30B
est: 1.59B (+44.9%)
|
2.86B
est: 1.92B (+49.1%)
|
2.29B
est: 2.09B (+9.3%)
|
2.09B
est: 2.23B (-6.4%)
|
| EPS |
100.60
est: 83.07 (+21.1%)
|
-87.52
est: 45.30 (-293.2%)
|
-86.48
est: 54.10 (-259.9%)
|
90.06
est: 53.40 (+68.7%)
|
88.57
est: 87.90 (+0.8%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-28 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-27 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-26 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-25 | S- | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-22 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-21 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-20 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-19 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-18 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-15 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-14 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-13 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-12 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-11 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-08 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-07 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-01 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-22 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-17 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-16 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hideaki Tamada | President & Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7807.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
